Fibroblast Growth Factor 2: Role in Health and Disease

Fibroblast growth factor 2, commonly called FGF2, is one of the body’s most versatile signaling proteins, involved in processes ranging from wound healing and blood vessel formation to brain cell renewal and heart protection. What makes it unusual is that the same molecule can play a beneficial role in one tissue and a harmful one in another, and it even exists in multiple forms within a single cell, each with distinct behavior. Understanding how FGF2 operates across different organs and diseases reveals why it has become a target for therapies as varied as wound dressings, cancer drugs, and experimental treatments for anxiety and neurodegeneration.

What FGF2 Actually Is

FGF2 is a protein made from a single gene, but through a quirk of how cells read that gene, it gets produced in more than one size. The smallest version, roughly 18 kilodaltons, is the one most studied. It gets released from cells and works by landing on receptor proteins on the surface of neighboring cells, triggering growth and survival signals. The larger versions, collectively called high molecular weight forms, tend to stay inside the cell that made them and accumulate in the nucleus, where they act independently of the surface receptors entirely.¹ This split personality means FGF2 can simultaneously influence what happens outside the cell and what happens inside the nucleus, giving it a remarkably broad reach.²

The small, secreted form of FGF2 does not leave cells by the usual route. Most secreted proteins are packaged in vesicles and shuttled through the cell’s internal transport network. FGF2 skips all of that. Instead, it gathers at the inner surface of the cell membrane, clusters together, creates localized stress in the membrane’s lipid layers, and essentially punches a tiny pore through which it exits. Once on the outer surface, sugar-coated anchor proteins called heparan sulfate proteoglycans grab the FGF2 clusters, pull them apart, and present the individual molecules to signaling receptors.³ Those same heparan sulfate molecules are required for FGF2 to properly bind its receptors, making them essential middlemen in the signaling chain.⁴

Wound Healing and Tissue Repair

One of FGF2’s most studied roles is in healing damaged tissue. When skin is injured, controlled delivery of FGF2 to a wound accelerates closure through several overlapping effects: it drives cell proliferation, stimulates the secretion of another growth factor (VEGF) to re-establish blood supply, promotes collagen deposition, and encourages the formation of granulation tissue, the scaffold on which new skin is built. In animal models, wound dressings engineered to slowly release FGF2 also boost the maturation of new blood vessels by increasing expression of markers associated with vessel stability.⁵

Because FGF2 breaks down quickly if simply applied to a wound, researchers have developed delivery systems to protect it and release it gradually. One approach uses an injectable self-healing hydrogel that adapts to irregular wound shapes and slowly lets FGF2 diffuse out over time. In experimental wound models, this hydrogel significantly promoted new blood vessel formation, collagen buildup, and granulation tissue while also reducing inflammation.⁶ The challenge in translating these results to routine clinical use remains ensuring the protein stays active long enough at the right concentration.

Building and Remodeling Blood Vessels

FGF2 is one of the strongest known triggers of angiogenesis, the sprouting of new blood vessels from existing ones. Part of its power comes from its ability to amplify other pro-angiogenic signals. When FGF2 acts on endothelial cells (the cells lining blood vessels), it causes them to produce more VEGF, establishing an autocrine feedback loop: FGF2 tells the cell to make VEGF, and VEGF then feeds back onto the same cell to promote further growth. Blocking VEGF with a neutralizing antibody inhibits endothelial cell proliferation that FGF2 kicked off, confirming that FGF2 does not act alone but orchestrates a broader cascade.⁷

This relationship between FGF2 and VEGF will come up again in the context of cancer, where it becomes a liability rather than a benefit. But in healthy tissues, angiogenesis driven by FGF2 is crucial for repairing damage after heart attacks, healing fractures, and sustaining regenerating tissues.

Protecting the Heart After a Heart Attack

Some of the most striking evidence for FGF2’s protective role comes from heart research. In mouse models of heart attack (ischemia-reperfusion injury), animals genetically lacking FGF2 fared dramatically worse than normal animals. Hearts from mice without FGF2 recovered only about 27% of their pumping ability after a blockage, compared with 63% recovery in normal hearts. When researchers engineered mice to overexpress FGF2, recovery jumped to 88%, and the area of dead heart muscle was cut from roughly 30% of the at-risk zone down to about 13%.⁸

This protection does not appear to work by improving blood flow during the crisis. Coronary flow and capillary density were the same across all groups, suggesting FGF2 protects heart cells through internal survival signals rather than by boosting circulation. Follow-up work has identified nitric oxide signaling and ATP-sensitive potassium channels as two downstream pathways through which FGF2 shields heart cells. Blocking either of these pathways during the ischemic period abolished the benefit.⁹

In a more clinically realistic closed-chest model, mice lacking FGF2 again showed larger areas of dead tissue, worse heart function at one and seven days after injury, more cell death in the acute phase, and reduced blood vessel density around the infarct over the following week.¹⁰ Together, these studies paint FGF2 as an essential part of the heart’s built-in damage-control machinery, acting both as an acute shield and a longer-term repair coordinator.

Brain Health, Neurogenesis, and Mood

FGF2 plays a surprisingly important role in the brain, especially in the hippocampus, the region central to memory and emotional regulation. After brain injuries such as seizures or stroke, FGF2 levels rise in the surrounding tissue. This is not just a bystander response: mice genetically lacking FGF2 show substantially less production of new neurons in the hippocampus after these injuries. When researchers restored FGF2 to those mice using gene delivery, the birth of new neurons rebounded to levels seen in normal animals, demonstrating that FGF2 is both necessary and sufficient for injury-induced neurogenesis in the adult hippocampus.¹¹

This regenerative function has caught the attention of Alzheimer’s disease researchers. In mouse models of Alzheimer’s, delivering the FGF2 gene to the hippocampus boosted the birth and survival of new neurons and enhanced clearance of amyloid-beta, the protein fragment that accumulates in Alzheimer’s plaques.¹² These are animal results, and translating them to humans remains a major hurdle, but they suggest FGF2 could have a role beyond simply growing new cells: it may help clear the molecular debris of neurodegeneration.

Perhaps the most intriguing FGF2-brain connection involves mood. Postmortem studies of people who had depression found reduced FGF2 expression in the brain. Animal research has deepened this link. Rats bred for high anxiety have significantly lower hippocampal FGF2 levels compared with their low-anxiety counterparts, and administering FGF2 directly into the brain reduces anxiety-like behavior in the high-anxiety animals without affecting the already-calm ones.¹³ Even a single dose of FGF2 given early in life can reshape the developmental trajectory of the hippocampus and lower anxiety in adulthood in vulnerable rats, while having no discernible effect on animals that are not predisposed to anxiety.¹⁴

This pattern has been observed in humans as well. Clinic-referred children with anxiety and depressive symptoms had lower circulating FGF2 levels than non-referred children, and those levels correlated negatively with the severity of anxiety, depression, and behavioral avoidance.¹⁵ FGF2 is far from being the whole story in mood disorders, but it seems to function as a kind of resilience factor, buffering the brain’s emotional circuitry against stress and anxiety.

Cancer and the Problem of a Double-Edged Signal

FGF2’s abilities that heal wounds and protect the heart become a liability in cancer. Tumors hijack FGF signaling to feed their own growth, build blood supply, and recruit support cells. FGF2 drives tumor angiogenesis and also promotes the recruitment of pericytes, the cells that wrap around blood vessels and stabilize them. In experiments where FGF2 expression was silenced in tumors, both angiogenesis and pericyte coverage dropped markedly, and tumor growth slowed.¹⁶

One of the most clinically significant problems with FGF2 in cancer is its role in resistance to anti-VEGF therapies. Drugs like bevacizumab work by blocking VEGF, starving tumors of their blood supply. But in many patients, tumors eventually escape this blockade. FGF2 sits at the top of the list of compensatory factors that enable this escape.¹⁷ Research has shown that after chronic anti-VEGF treatment, pericytes in the tumor microenvironment ramp up FGF2 production, which then activates FGF receptors on endothelial cells and restores tumor blood vessel growth through a parallel pathway the anti-VEGF drug cannot touch.¹⁸ In head and neck cancers resistant to bevacizumab, tumors upregulate an entire pro-angiogenic gene signature that converges on FGF2 via ERK signaling.¹⁹

These findings have pushed researchers toward dual-targeting strategies. Blocking both FGF and VEGF pathways simultaneously appears more effective at suppressing tumor angiogenesis than blocking either one alone.²⁰ Beyond angiogenesis, FGF2 also drives cancer cells directly: in ovarian cancer cells, FGF2 activates intracellular growth pathways that reduce expression of E-cadherin, a molecule that keeps cells stuck together, potentially contributing to tumor spread.²¹ FGFR-targeting drugs, including small-molecule inhibitors of FGF receptor kinases, have entered clinical use, but resistance to those drugs also develops.²² Newer approaches combine FGFR blockade with other targeted therapies. In cancers that start out with high levels of both FGFR1 and FGF2, adding an FGFR inhibitor to the existing targeted drug prevents the cancer cells from reactivating backup growth signals and enhances cell death.²³

Fighting Fibrosis Rather Than Fueling It

Given that FGF2 promotes cell growth and tissue remodeling, you might expect it to worsen fibrosis, the buildup of stiff scar tissue that damages organs. The opposite appears to be true, at least for the small secreted form of FGF2. In the heart, the small form significantly reduced the ability of TGF-beta (the master driver of scar formation) to activate myofibroblasts, the cells that produce excess collagen and remodel heart tissue after injury.²⁴

In the lung, FGF2 shows a similar anti-fibrotic effect. It strongly inhibited baseline and TGF-beta-driven expression of collagen and the transformation of fibroblasts into myofibroblasts in both mouse and human lung cells. In animal models of bleomycin-induced pulmonary fibrosis, FGF2 reduced overall fibrosis.²⁵ This anti-fibrotic profile is somewhat counterintuitive for a growth factor, and it hints that FGF2 may serve as a natural brake on excessive scarring in multiple organs.

Aging, Muscle Stem Cells, and a Too-Much-of-a-Good-Thing Problem

In young, healthy muscle, satellite cells (the resident stem cells responsible for muscle repair) sit dormant until an injury calls them into action. FGF signaling is one of the cues that wakes them up. But aging introduces a twist: old muscle fibers begin producing FGF2 even when there is no injury. This chronic, low-level FGF2 signal rouses a subset of satellite cells from their resting state, depleting the pool of stem cells available for actual repairs. The result is diminished regenerative capacity over time.²⁶

Aged satellite cells that manage to stay dormant do so partly by ramping up expression of Sprouty 1, a protein that dampens FGF receptor signaling. Experimentally removing Sprouty 1 from aged satellite cells mimics the depletion seen in old muscle. Conversely, blocking the FGF receptor or boosting Sprouty 1 prevents stem cell loss. The broader picture includes additional age-related changes that reduce FGF responsiveness when it is actually needed: mislocalization of integrins on the cell surface, less fibronectin in the surrounding tissue, and changes in heparan sulfate composition all conspire to make satellite cells deaf to helpful FGF signals while still vulnerable to the chronic background noise.²⁷ It is a clear case where context determines whether FGF2 is friend or foe: a well-timed burst helps, but a persistent drip erodes the system.

FGF2 in Fat and Metabolism

FGF2’s relationship with fat tissue is surprisingly dose-dependent. At low concentrations, FGF2 actually promotes the development of fat cells from stem cells. At higher concentrations, however, it flips into a suppressive mode, maintaining sustained activation of growth-pathway signals that block fat cell differentiation. In obese mice fed a high-fat diet, FGF2 levels in fat tissue were lower than in lean controls, suggesting the body’s FGF2 tone may be linked to how readily fat depots expand.²⁸

Mice completely lacking FGF2 show enhanced heat production in both brown and beige fat, the types of fat tissue that burn calories rather than store them. These knockout mice are protected against weight gain and fatty liver disease on a high-fat diet, apparently because removing FGF2 unlocks expression of a key thermogenic protein (UCP1) that is normally kept in check by FGF2.²⁹ This means FGF2 normally acts as a brake on calorie-burning fat, which is the opposite of what you might expect from a growth factor. The metabolic effects of FGF2 also vary by anatomical location: fat stem cells from breast tissue respond to FGF2 with greater proliferation and fat-forming activity than cells from abdominal or thigh fat, mediated by differences in a specific internal signaling pathway.³⁰

Potential As a Biomarker

Given FGF2’s involvement in blood vessel biology, researchers have tested whether circulating FGF2 levels might predict cardiovascular disease progression. In a study of patients with chronic kidney disease, a population at high risk for atherosclerosis, higher plasma FGF2 was associated with lower odds of plaque progression over two years. Patients in the highest third of FGF2 levels had roughly half the risk of worsening atherosclerosis compared with those in the lowest third.³¹ Whether FGF2 is actively protecting those patients’ arteries or merely reflecting better overall vascular health is not yet clear, but the association is consistent with FGF2’s known roles in vessel maintenance and tissue repair.

Optic Nerve Repair and Bone Regeneration

FGF2 has shown promise in tissues that are notoriously difficult to regenerate. After optic nerve injury in adult animals, delivering the FGF2 gene to retinal ganglion cells stimulated those cells to regrow axons into the optic nerve, an environment usually hostile to regeneration. The effect on axon growth was separable from simple cell survival: FGF2 only transiently protected the injured neurons from dying, yet the axon-regrowth effect persisted, implying it was actively promoting regeneration rather than just keeping cells alive.³²

In bone, FGF2 is considered one of several candidate growth factors for regenerative therapy. Its expression rises and falls in coordinated patterns during fracture healing, and genetically modified mice lacking or overexpressing FGF2 show altered bone repair, pointing to it as a meaningful regulator of the process. Researchers have used controlled-release systems similar to those in wound healing to deliver FGF2 to bone defects, with encouraging early results in generating new tissue, including adipose tissue engineered from collagen matrices combined with slow-release FGF2 microspheres.³³

FGF2 Beyond Mammals

FGF2’s influence extends across species in ways that illuminate both its evolutionary conservation and its versatility. In sheep, FGF2 is specifically expressed in horn and skin tissues, with significantly higher levels in large-horned breeds than in small-horned ones. Cross-species comparisons between domestic sheep and bighorn sheep reveal a species-specific amino acid variant in the FGF2 protein that may contribute to differences in horn shape and size.³⁴ These findings are a reminder that FGF2 is not merely a repair molecule; it has been co-opted throughout evolution to shape diverse physical structures, from the branching networks of blood vessels in a human heart to the keratin-based horns on a sheep’s skull.